查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887156

前列腺癌激素治療市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032 年）

Prostate Cancer Hormone Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

前列腺癌荷爾蒙治療市場成長因素

隨著前列腺癌發生率的持續上升和治療創新技術的快速發展，全球前列腺癌激素治療市場呈現強勁增長勢頭。根據最新的產業預測，該市場預計在 2024 年達到 160.7 億美元，並在 2025 年達到 204.4 億美元。預計到 2032 年，該市場規模將飆升至 799.3 億美元，顯示全球醫療保健系統對基於荷爾蒙療法的治療方案有著強勁的需求。 2024 年，北美地區憑藉先進的醫療保健基礎設施、完善的報銷政策以及對早期癌症診斷的高度重視，以 51.71% 的市場佔有率佔主導地位。

荷爾蒙療法仍是前列腺癌治療的基石。這種療法也稱為雄性激素剝奪療法 (ADT)，它能降低驅動腫瘤生長的荷爾蒙水平，廣泛用於轉移性和晚期疾病的治療。隨著全球癌症負擔的加重——2022 年全球癌症研究聯盟 (GLOBOCAN 2022) 記錄了 147 萬例前列腺癌病例，使其成為第四大癌症發病原因——人們對荷爾蒙療法作為核心治療方法的依賴性日益增強。

市場驅動因素

先進荷爾蒙療法的研發是推動市場發展的關鍵因素。各大製藥公司正在推出新的雄性激素受體抑制劑和新一代基於促性腺激素釋放激素 (GnRH) 的療法，以克服抗藥性並改善患者預後。 2023 年 11 月，安斯泰來製藥和輝瑞的 XTANDI 獲得 FDA 批准用於治療非轉移性去勢敏感性前列腺癌，擴大了治療選擇的範圍。

強大的研發管線和不斷增加的臨床試驗持續加速治療創新。 除了全球前列腺癌發生率不斷上升外，已開發國家先進治療手段的普及也支撐著市場的持續成長。

市場限制因子

一個主要的限制因素是對傳統雄性激素剝奪療法（ADT）抗藥性的日益增強。隨著時間的推移，前列腺癌細胞可能會發生突變，持續產生雄激素，從而降低治療效果。例如，西爾維斯特綜合癌症中心於2024年1月發表的一項研究表明，即使在激素抑制療法期間，3β-羥基類固醇脫氫酶1（3BHSD1）也能使腫瘤再生雄激素，加速疾病進展。這種抗藥性對治療效果構成挑戰，並限制了長期治療的實施。

市場挑戰

接受荷爾蒙治療的患者常常會出現嚴重的副作用，這可能導致治療順從性下降。勃起功能障礙和性慾減退是常見的併發症。 2020 年 Elsevier 的一項研究發現，82% 的 ADT 患者出現勃起功能障礙，64% 的患者報告性慾下降，對生活​​品質有負面影響。這些不良反應仍然是治療持續性的重大障礙。

市場機會

聯合療法具有巨大的未來潛力。製藥公司正在積極探索 PARP 抑制劑與 ADT 的聯合應用，以克服抗藥性並延長存活期。 2025 年 2 月，TALAPRO-2 試驗表明，他拉唑帕尼（Tarzena）和恩扎盧胺（Xtandi）的聯合用藥可使 HRR 缺陷型轉移性前列腺癌患者的總生存期延長 14 個月，死亡風險降低 38%。 這些結果凸顯了聯合療法在塑造未來治療格局方面的巨大潛力。

市場區隔概覽

依藥物類別

2024年，GnRH激動劑憑藉其強大的睪固酮抑製作用佔了最大的市場佔有率。 CAMCEVI等產品的監管批准持續鞏固了這個細分市場。由於多項新藥核准和臨床適應症的擴大，GnRH受體拮抗劑和雄激素受體抑制劑預計將顯著成長。

依疾病類型

2024年，轉移性去勢抵抗性前列腺癌（mCRPC）細分市場引領市場，這主要得益於發病率的上升和獲批標靶療法數量的增加。 隨著各公司擴大適應症範圍，非轉移性去勢抵抗性前列腺癌 (CRPC) 市場預計將顯著成長。

依給藥途徑

口服給藥途徑佔最大佔有率，這主要得益於其給藥方便以及仿製藥的普及（例如，Amneal 公司獲得 FDA 批准的醋酸阿比特龍仿製藥）。由於新的注射劑型正在研發中，腸外給藥途徑的市佔率也持續成長。

按分銷管道

醫院藥房佔主導地位，這得益於醫院擁有專業的癌症治療中心，並且治療過程由醫生監督。 同時，隨著藥物可近性的提高，零售藥局和線上藥局也在穩定成長。

區域展望

北美

由於前列腺癌的高發病率和先進療法的廣泛應用，預計到2024年，北美市場規模將達到83.1億美元。強大的研發基礎和FDA的批准是該地區主導的重要因素。

歐洲

歐洲擁有第二大市場佔有率，這得益於監管機構的批准。 2024年，NICE（英國國家衛生與臨床優化研究所）推薦ORGOVYX作為經濟有效的治療選擇。

亞太地區

由於人口老化和治療藥物核准數量的增加，預計亞太地區將實現最快成長。 2024年7月，中國國家藥品監督管理局（NMPA）核准Estandi用於治療轉移性疾病。

拉丁美洲、中東和非洲

預計在合作不斷擴大和前列腺癌治療可及性逐步提高的推動下，該地區將實現溫和增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 2024年主要國家及地區攝護腺癌盛行率
  • 主要公司產品線分析
  • 替代療法概述
  • 市場主要新創企業
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）
  • 新冠疫情的影響市場

第五章：全球前列腺癌荷爾蒙治療市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 按藥物類別劃分
    • 雄性激素受體抑制劑
    • 促性腺激素釋放激素 (GnRH) 激動劑
    • 促性腺激素釋放激素 (GnRH) 受體拮抗劑
    • 其他
  • 市場分析、洞察與預測 - 按給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測 - 按疾病狀態劃分
    • 轉移性去勢抵抗性攝護腺癌
    • 非轉移性去勢抵抗性攝護腺癌癌症
  • 市場分析、洞察與預測 - 按銷售管道劃分
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美前列腺癌激素治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲前列腺癌激素治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區前列腺癌激素治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲前列腺癌激素治療市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東和非洲前列腺癌激素療法市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 安斯泰來藥廠式會社
    • 輝瑞公司
    • 強生服務公司
    • 費林製藥公司
    • 住友製藥株式會社（Myovant Sciences） GmbH)
    • 艾伯維公司 (AbbVie Inc.)
    • 阿斯特捷利康 (AstraZeneca)
    • Accord BioPharma, Inc.
    • 拜耳股份公司 (Bayer AG)
Product Code: FBI112836

Growth Factors of prostate cancer hormone therapy Market

The global prostate cancer hormone therapy market is witnessing robust growth as prostate cancer prevalence continues to rise and treatment innovations advance rapidly. According to the latest industry estimates, the market was valued at USD 16.07 billion in 2024, is expected to reach USD 20.44 billion in 2025, and is projected to surge to USD 79.93 billion by 2032, demonstrating the strong demand for hormone-based treatment options across global healthcare systems. In 2024, North America dominated the market with a 51.71% share, supported by advanced healthcare infrastructure, strong reimbursement policies, and high awareness of early cancer diagnosis.

Hormone therapy remains a cornerstone of prostate cancer management. Also known as Androgen Deprivation Therapy (ADT), this treatment reduces hormone levels that fuel tumor growth and is widely used in metastatic and advanced-stage cancers. With global cancer burden intensifying-GLOBOCAN 2022 recorded 1.47 million prostate cancer cases, making it the 4th most common cancer-there is rising dependence on hormone therapy as a core treatment approach.

Market Drivers

The development of advanced hormonal therapies is a major market driver. Leading pharmaceutical companies are introducing new androgen receptor inhibitors and next-generation GnRH-based therapies to overcome resistance and improve patient outcomes. In November 2023, Astellas Pharma and Pfizer received FDA approval for XTANDI for non-metastatic Castration-Sensitive Prostate Cancer, enabling broader treatment use.

Strong R&D pipelines and increasing clinical trials continue to accelerate therapeutic innovation. The rising global incidence of prostate cancer, coupled with expanding access to advanced therapies in developed nations, also supports continuous market growth.

Market Restraints

A significant restraint is the growing resistance to conventional ADT. Over time, prostate cancer cells may mutate and continue producing androgens, diminishing therapeutic effectiveness. For instance, research in January 2024 by Sylvester Comprehensive Cancer Center revealed that the enzyme 3BHSD1 enables tumors to regenerate androgens even during hormone suppression therapy, accelerating disease progression. This resistance challenges treatment efficacy and limits long-term therapy adoption.

Market Challenges

Patients undergoing hormonal therapy often experience substantial side effects, making treatment adherence challenging. Erectile dysfunction and libido loss are common complications. A study published by Elsevier in 2020 reported that 82% of ADT patients experienced erectile problems, while 64% reported loss of sexual desire, negatively affecting quality of life. Such adverse effects remain a major barrier to therapy continuation.

Market Opportunities

Combination therapies offer significant future opportunities. Pharmaceutical companies are increasingly exploring combinations of PARP inhibitors with ADT to address resistance and extend survival. In February 2025, the TALAPRO-2 trial demonstrated that combining talazoparib (Talzenna) with enzalutamide (Xtandi) provided a 14-month improvement in overall survival for HRR-deficient metastatic prostate cancer patients, with a 38% reduction in mortality risk. These outcomes highlight the strong potential of combination therapy in shaping the future treatment landscape.

Segmentation Overview

By Drug Class

In 2024, GnRH agonists held the leading share due to high effectiveness in testosterone suppression. Regulatory approvals for products like CAMCEVI continue strengthening this segment. GnRH receptor antagonists and androgen receptor inhibitors are expected to grow substantially due to multiple new approvals and expanded clinical indications.

By Disease State

The metastatic castration-resistant prostate cancer (mCRPC) segment dominated in 2024, driven by rising incidence and increased approvals of targeted therapies. The non-metastatic CRPC segment is set for strong growth as companies broaden their indications.

By Route of Administration

The oral segment held the largest share due to ease of administration and growing generic launches, such as Amneal's FDA-approved generic Abiraterone Acetate. The parenteral segment continues to expand with new injectable formulations under trial.

By Distribution Channel

Hospital pharmacies lead due to specialized cancer treatment centers and physician-supervised therapy administration. Retail and online pharmacies are growing steadily due to improved drug accessibility.

Regional Outlook

North America

The market reached USD 8.31 billion in 2024, driven by high prostate cancer incidence and advanced therapeutic adoption. Strong R&D presence and FDA approvals contribute to regional dominance.

Europe

Europe holds the second-largest share, supported by healthcare authority endorsements. In 2024, NICE recommended ORGOVYX as a cost-effective treatment option.

Asia Pacific

Expected to be the fastest-growing region due to rising aging populations and increasing therapy approvals. In July 2024, China's NMPA approved XTANDI for metastatic disease.

Latin America & Middle East/Africa

Moderate growth is expected, driven by rising collaborations and gradual improvements in prostate cancer treatment access.

Conclusion

The global prostate cancer hormone therapy market is on a strong growth trajectory, rising from USD 16.07 billion in 2024 to USD 20.44 billion in 2025, and projected to reach USD 79.93 billion by 2032. With expanding treatment innovations, increasing approvals, and strong R&D momentum, hormone therapy remains central to the future of prostate cancer care.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Disease State

  • Metastatic Castration-Resistant Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Disease State
    • 5.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Disease State
    • 6.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Disease State
    • 7.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Disease State
    • 8.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Disease State
    • 9.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Disease State
    • 10.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 10.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Ferring Pharmaceuticals Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. AbbVie Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AstraZeneca
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Accord BioPharma, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bayer AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 2: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 4: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 5: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 7: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 8: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 9: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 10: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 12: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 13: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 14: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 15: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 17: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 18: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 19: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 20: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 22: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 24: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 25: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 27: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 28: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 29: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 30: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Prostate Cancer Hormone Therapy Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024 & 2032
  • Figure 3: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024 & 2032
  • Figure 5: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Prostate Cancer Hormone Therapy Market Value (USD billion), by Region, 2024 & 2032
  • Figure 7: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 8: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 9: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 10: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 11: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 12: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 13: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Prostate Cancer Hormone Therapy Market Value Share (%), By Country, 2024
  • Figure 17: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 18: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 19: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 20: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 21: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 22: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 23: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 28: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 29: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 30: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 31: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 32: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 33: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion),by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 38: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 39: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 40: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 41: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 42: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 43: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 48: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 49: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 50: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 51: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 52: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 53: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024

Figure 57: Global Prostate Cancer Hormone Therapy Market Share (%), By Company, 2024